Drugs / Patritumab
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02350712 | Dec 2014 → Mar 2016 | head and neck squamous cell carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01957280 | Jun → Oct 2013 | cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01479023 | Apr 2012 → Jan 2013 | carcinoma, lymphoma, sarcoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00730470 | Aug 2008 → Jul 2010 | cancer | U3 Pharma GmbH | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01512199 | Nov 2011 → Jan 2015 | breast cancer | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 1/2 | NCT01211483 | Sep 2010 → Oct 2013 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02633800 | Dec 2015 → Jan 2018 | head and neck neoplasm | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02134015 | Mar 2014 → Nov 2016 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-04 | Daiichi Sankyo | HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC daiichisankyo.com ↗ |
| 2021-01-29 | Daiichi Sankyo | New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented at WCLC 2020 daiichisankyo.com ↗ |
| 2020-09-18 | Daiichi Sankyo | Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020 daiichisankyo.com ↗ |
| 2020-09-15 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer daiichisankyo.com ↗ |
| 2020-08-07 | Daiichi Sankyo | Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer daiichisankyo.com ↗ |
| 2020-07-22 | Daiichi Sankyo | Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan daiichisankyo.com ↗ |
| 2016-10-25 | Daiichi Sankyo | Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer daiichisankyo.com ↗ |
| 2016-05-31 | Daiichi Sankyo | Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC) daiichisankyo.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Patritumab | “The purpose of this study was to evaluate the safety, dosimetry, and apparent receptor occupancy (RO) of [(64)Cu]DOTA-patritumab, a radiolabeled monoclonal antibody directed...” PMID 26567113 ↗ Jun 2016 |
| Known as | AMG 888 | “Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic...” NCT01512199 ↗ |
| Known as | U3-1287 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01211483 ↗ |
| Action | Inhibit | “patritumab blocks HER3 activation” PMID 31648099 ↗ Oct 2019 |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” NCT00730470 ↗ |
| Route | Intravenous | “IV Infusion” NCT00730470 ↗ |
| Target | ERBB3 | “a radiolabeled monoclonal antibody directed against HER3/ERBB3” PMID 26567113 ↗ Jun 2016 |